ZA201306813B - Antibodies that bind tgf-alpha and epiregulin - Google Patents

Antibodies that bind tgf-alpha and epiregulin

Info

Publication number
ZA201306813B
ZA201306813B ZA2013/06813A ZA201306813A ZA201306813B ZA 201306813 B ZA201306813 B ZA 201306813B ZA 2013/06813 A ZA2013/06813 A ZA 2013/06813A ZA 201306813 A ZA201306813 A ZA 201306813A ZA 201306813 B ZA201306813 B ZA 201306813B
Authority
ZA
South Africa
Prior art keywords
epiregulin
antibodies
alpha
bind tgf
tgf
Prior art date
Application number
ZA2013/06813A
Other languages
English (en)
Inventor
Catherine Brautigam Beidler
Ramona Judita Petrovan
Josef George Heuer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA201306813B publication Critical patent/ZA201306813B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/06813A 2011-04-06 2013-09-10 Antibodies that bind tgf-alpha and epiregulin ZA201306813B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472338P 2011-04-06 2011-04-06
PCT/US2012/030802 WO2012138510A1 (en) 2011-04-06 2012-03-28 Antibodies that bind tgf-alpha and epiregulin

Publications (1)

Publication Number Publication Date
ZA201306813B true ZA201306813B (en) 2015-04-29

Family

ID=45929050

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/06813A ZA201306813B (en) 2011-04-06 2013-09-10 Antibodies that bind tgf-alpha and epiregulin

Country Status (26)

Country Link
US (1) US8613921B2 (enExample)
EP (1) EP2694547B1 (enExample)
JP (1) JP2014515743A (enExample)
KR (1) KR101581517B1 (enExample)
CN (1) CN103459423B (enExample)
AR (2) AR085484A1 (enExample)
AU (1) AU2012240508B2 (enExample)
BR (1) BR112013023513A2 (enExample)
CA (1) CA2832256C (enExample)
CY (1) CY1116332T1 (enExample)
DK (1) DK2694547T3 (enExample)
EA (1) EA024921B1 (enExample)
ES (1) ES2539503T3 (enExample)
HR (1) HRP20150468T1 (enExample)
IL (1) IL228101A0 (enExample)
ME (1) ME02063B (enExample)
MX (1) MX2013011596A (enExample)
PL (1) PL2694547T3 (enExample)
PT (1) PT2694547E (enExample)
RS (1) RS54000B1 (enExample)
SG (1) SG193452A1 (enExample)
SI (1) SI2694547T1 (enExample)
TW (1) TWI454481B (enExample)
UA (1) UA110051C2 (enExample)
WO (1) WO2012138510A1 (enExample)
ZA (1) ZA201306813B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
KR102495473B1 (ko) * 2020-10-06 2023-02-06 서울대학교병원 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물
TWI859538B (zh) 2021-05-21 2024-10-21 美商美國禮來大藥廠 靶向表皮調節素(epiregulin)之化合物及方法
CN119213026A (zh) * 2022-03-04 2024-12-27 耶鲁大学 用于治疗和预防纤维化的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190858A (en) 1989-02-01 1993-03-02 Oncogene Science, Inc. Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof
JP5919593B2 (ja) 2006-10-11 2016-05-18 フージョン アンティボディーズ リミテッド 併用療法
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component

Also Published As

Publication number Publication date
US20120258109A1 (en) 2012-10-11
CA2832256C (en) 2016-02-09
DK2694547T3 (en) 2015-04-27
EA201370196A1 (ru) 2014-02-28
UA110051C2 (uk) 2015-11-10
RS54000B1 (sr) 2015-10-30
IL228101A0 (en) 2013-09-30
PL2694547T3 (pl) 2015-08-31
JP2014515743A (ja) 2014-07-03
MX2013011596A (es) 2013-12-09
KR101581517B1 (ko) 2015-12-30
PT2694547E (pt) 2015-06-01
EP2694547A1 (en) 2014-02-12
TW201300414A (zh) 2013-01-01
KR20130133274A (ko) 2013-12-06
AU2012240508B2 (en) 2014-10-23
AR085484A1 (es) 2013-10-02
SG193452A1 (en) 2013-10-30
CY1116332T1 (el) 2017-02-08
HRP20150468T1 (hr) 2015-06-05
AU2012240508A1 (en) 2013-08-29
WO2012138510A1 (en) 2012-10-11
SI2694547T1 (sl) 2015-05-29
CN103459423A (zh) 2013-12-18
NZ614198A (en) 2015-09-25
ME02063B (me) 2015-05-20
AR123912A2 (es) 2023-01-25
ES2539503T3 (es) 2015-07-01
EA024921B1 (ru) 2016-11-30
US8613921B2 (en) 2013-12-24
TWI454481B (zh) 2014-10-01
BR112013023513A2 (pt) 2016-11-22
CA2832256A1 (en) 2012-10-11
HK1190410A1 (en) 2014-07-04
CN103459423B (zh) 2016-03-02
EP2694547B1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL288203A (en) Meditopes and meditope-binding antibodies and uses thereof
IL276573A (en) Antibodies against PD–L1 and uses thereof
IL259436A (en) Antibodies against 3angptl and their uses
IL251697A0 (en) Antibodies against 3erbb and their uses
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
IL232399A0 (en) Anti-2fgfr antibodies and their use
SG11201402283PA (en) Anti il-36r antibodies
SI2869837T1 (sl) Protitelesa proti teofilinu in postopki uporabe
IL228101A0 (en) Antibodies that bind tgf-alpha and epirogulin